Daiichi Sankyo Company, Limited (DSNKY)
| Market Cap | 43.42B |
| Revenue (ttm) | 11.42B |
| Net Income (ttm) | 1.56B |
| Shares Out | n/a |
| EPS (ttm) | 0.82 |
| PE Ratio | 27.78 |
| Forward PE | n/a |
| Dividend | 0.41 (1.81%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 2,533 |
| Average Volume | 388,109 |
| Open | 23.48 |
| Previous Close | 23.28 |
| Day's Range | 23.14 - 23.83 |
| 52-Week Range | 20.92 - 42.48 |
| Beta | 0.33 |
| RSI | 49.24 |
| Earnings Date | Apr 25, 2025 |
About Daiichi Sankyo Company
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhi... [Read more]
Financial Performance
In 2023, Daiichi Sankyo Company's revenue was 1.60 trillion, an increase of 25.28% compared to the previous year's 1.28 trillion. Earnings were 200.73 billion, an increase of 83.84%.
Financial numbers in JPY Financial StatementsNews
ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer
DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca's ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2 positive metastatic patient pop...
Daiichi Sankyo: Good Diversification Tool For U.S. Investors
Daiichi Sankyo and AstraZeneca get EU approval for Datroway
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
The European Commission on Friday approved AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSKNY) Enhertu (trastuzumab deruxtecan) as a monotherapy for a type of breast cancer. The approval...
DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with a fluoropyrimidine chemotherapy (5-FU or capecitabine) and Mer...
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
The Association of the British Pharmaceutical Industry (ABPI) is urging ministers to address excessive levies on manufacturers to ensure the sector remains competitive globally. The life sciences indu...
Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines
BERKELEY, Calif.--(BUSINESS WIRE)-- #RNA--Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines.
Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial
Phase 3 results confirm the efficacy of Daiichi Sankyo and AstraZeneca's ENHERTU in second-line metastatic gastric cancer DESTINY-Gastric04 will be unblinded at interim analysis based on the superior ...
AstraZeneca's metastatic breast cancer treatment gets EU recommendation
AstraZeneca and Daiichi Sankyo said on Friday that the European Medicines Agency endorsed ENHERTU for the treatment of metastatic breast cancer.
AstraZeneca Blames 'Toxic' Climate As It Walks Away from Over $550 Million UK Vaccine Plant
AstraZeneca Plc (NASDAQ: AZN) has abandoned plans for a $554.32 million (450 million pounds) vaccine manufacturing facility in the U.K. following disagreements with government officials over state su...
Q3 2025 Daiichi Sankyo Co Ltd Earnings Presentation Transcript
Q3 2025 Daiichi Sankyo Co Ltd Earnings Presentation Transcript
Incoming Daiichi Sankyo CEO shares business roadmap going forward
Hiroyuki Okuzawa, current COO and incoming CEO of Daiichi Sankyo, talks about the pharmaceutical company's product pipeline, including its cancer treatments, and its global partnerships with AstraZene...
Incoming Daiichi Sankyo CEO shares business roadmap going forward
Hiroyuki Okuzawa, current COO and incoming CEO of Daiichi Sankyo, talks about the pharmaceutical company's product pipeline, including its cancer treatments, and its global partnerships with AstraZene...
Daiichi Sankyo Company, Limited 2024 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2024 Q3 earnings call.
Daiichi Sankyo sees ENHERTU sales reaching ¥539.9B in FY2024 amid oncology momentum
Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call Transcript
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q3 2024 Earnings Call Transcript January 31, 2025 1:00 AM ETCompany ParticipantsKentaro Asakura - VP of...
Daiichi Sankyo reports 9M results
Daiichi Sankyo (DSKYF) reports strong financial results with 9M diluted earnings per share of 109.58 JPY and revenue growth of 16.6% year-over-year.
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Next CEO
Daiichi Sankyo has announced that Hiroyuki Okuzawa will assume the role of CEO, succeeding Sunao Manabe, effective April 1, 2025. The company’s board of directors, acting on the recommendation of the ...
Daiichi Sankyo appoints Hiroyuki Okuzawa as CEO
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. M...
TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse
The first patient has been dosed in the TROPION-Lung12 phase 3 trial evaluating the efficacy and safety of adjuvant DATROWAY ® (datopotamab deruxtecan) plus rilvegostomig or rilvegostomig monotherapy ...
ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings Daiichi ...
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
First approval in the US for AstraZeneca and Daiichi Sankyo's DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy DATROWAY is ...
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
First approval in the U.S. for Daiichi Sankyo and AstraZeneca's DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death versus chemotherapy Second ...